A Connecticut-based pharmaceutical company has agreed to pay $95 million to settle claims that the company promoted drugs for off-label uses and paid kickbacks to medical providers as an incentive for prescribing the drugs.
Boehringer Ingelheim Pharmaceuticals Inc., headquartered in Ridgefield, will pay the federal government and several states’ Medicaid programs the $95 million after allegations surfaced regarding four drugs the company marketed – the stroke prevention drug Aggrenox, the chronic obstructive pulmonary disease drugs Atrovent and Combivent, and the blood pressure drug Micardis.
